A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
about
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerLoss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.Time, space, and disorder in the expanding proteome universe.c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease.Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin.Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.TP53 mutations, expression and interaction networks in human cancersAccelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroCisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.Modeling and Targeting MYC Genes in Childhood Brain Tumors.The MYCN Protein in Health and Disease.Family matters: How MYC family oncogenes impact small cell lung cancer.Association between the functional polymorphism Ile31Phe in the AURKA gene and susceptibility of hepatocellular carcinoma in chronic hepatitis B virus carriers.Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain.Transcriptome Analysis Uncovers a Growth-Promoting Activity of Orosomucoid-1 on Hepatocytes.An in vivo transfection system for inducible gene expression and gene silencing in murine hepatocytes.Combinatorial genetics in liver repopulation and carcinogenesis with a novel in vivo CRISPR activation platform.Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle.Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.Spatial Tissue Proteomics Quantifies Inter- and Intratumor Heterogeneity in Hepatocellular Carcinoma (HCC).Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid.Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.Identification of The Aberrantly Expressed LncRNAs in Hepatocellular Carcinoma: A Bioinformatics Analysis Based on RNA-sequencing.Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology.Identification of key candidate genes and pathways in hepatocellular carcinoma by integrated bioinformatical analysis.Analysis of potential genes associated with primary cilia in bladder cancerThe functional diversity of Aurora kinases: a comprehensive reviewTherapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells
P2860
Q28771715-864C7EDB-EC9D-4E32-AB08-9DE8C5FEF7EDQ29871425-EC390D2E-29C0-41BA-B587-18B9B7C040FEQ30398082-E9459007-1AC1-474F-9DF1-BE9CAF24952CQ33608524-1456D1D4-446E-4D80-A681-E7F4D7F4395DQ37316239-008AB02B-8526-4DD3-949E-788C331888EFQ37399824-0E6BA60E-7E55-4217-8C6F-1F980518561BQ37702327-6F298C6D-9AAA-482F-AF91-FC6561F174EAQ38730798-0F9FEBE0-8EDF-4ABC-8315-98D712DA263AQ38833185-E2191274-EB6E-4783-AE9E-DC281D3A7012Q39028389-E9055634-1A0A-4F44-AF91-64EC435B4A13Q39195507-1F4760E9-64A2-46CF-9EB2-AFFD7DEF442CQ39208675-E1AA2044-20EE-4F88-9A21-CE2F21FE9F11Q39454070-B24BB588-BDF0-45D5-AAA0-203E63CE90AAQ40043160-1C74DEBA-8DBD-4F2E-BD4B-4AECE623F0DDQ41670848-1CB17E1D-714D-4798-B2B8-4F0950E8B4F4Q41868025-A5E80AFE-20D2-417F-ABE0-3CC616379499Q42651977-EA48F338-AA46-4758-9EE2-B4AA532A67C4Q44620413-63416941-78D9-4FDE-BD13-9F291EF01857Q46571818-B665295D-0F33-47B5-9466-A017C2423AABQ47101236-53EA9135-0416-4B8B-B614-487F940DF315Q49421936-A65C067F-D03E-4B1A-A1E0-E1D58CE8D406Q49832163-8BDB505D-F4B3-4500-A24D-6D469249624EQ52568671-BF2E5C01-A71C-43B2-A0F8-B3726AC72DA7Q52671240-E54854F1-3FF5-4977-BDFD-D3C31144C0A2Q52723073-5B206DC9-1846-4F8C-9CDA-346A7F527919Q55033899-9085300E-B76C-4367-8A28-82A7F89D8988Q55359727-017F679C-D73E-49BD-A00B-2FEFCFD091D6Q58693846-C2A9115A-4EA7-4216-9E4C-99BFFC1D2C48Q58719157-E255E6C1-999C-441E-B103-085476B44D71Q58727408-63564DC7-43BC-4C23-B0CC-5B4FA42E9F36
P2860
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
A MYC-aurora kinase A protein ...... t in p53-altered liver cancer.
@en
A MYC-aurora kinase A protein ...... t in p53-altered liver cancer.
@nl
type
label
A MYC-aurora kinase A protein ...... t in p53-altered liver cancer.
@en
A MYC-aurora kinase A protein ...... t in p53-altered liver cancer.
@nl
prefLabel
A MYC-aurora kinase A protein ...... t in p53-altered liver cancer.
@en
A MYC-aurora kinase A protein ...... t in p53-altered liver cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
A MYC-aurora kinase A protein ...... t in p53-altered liver cancer.
@en
P2093
Anja Hohmeyer
Daniel Dauch
Lars Zender
Lisa Hoenicke
Nisar P Malek
Przemyslaw Bozko
Ramona Rudalska
Tae-Won Kang
Thomas Longerich
Torsten Wuestefeld
P2860
P2888
P304
P356
10.1038/NM.4107
P407
P50
P577
2016-05-23T00:00:00Z
P6179
1027948943